학술논문

Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report From the NKF-ASN Task Force
Document Type
article
Source
American Journal of Kidney Diseases. 78(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Kidney Disease
8.1 Organisation and delivery of services
Health and social care services research
Renal and urogenital
Black or African American
Glomerular Filtration Rate
Health Status Disparities
Healthcare Disparities
Humans
Racial Groups
Renal Insufficiency
Chronic
United States
creatinine
estimated glomerular filtration rate
estimating equation
ethnicity
filtration marker
health care equity
health disparities
kidney disease
kidney disease diagnosis
laboratory medicine
medical decision making
patient-centered care
public health
race
race coefficient
racism
renal function
social determinants of health
Public Health and Health Services
Urology & Nephrology
Clinical sciences
Language
Abstract
For almost 2 decades, equations that use serum creatinine, age, sex, and race to estimate glomerular filtration rate (GFR) have included "race" as Black or non-Black. Given considerable evidence of disparities in health and health care delivery in African American communities, some regard keeping a race term in GFR equations as a practice that differentially influences access to care and kidney transplantation. Others assert that race captures important non-GFR determinants of serum creatinine and its removal from the calculation may perpetuate other disparities. The National Kidney Foundation (NKF) and American Society of Nephrology (ASN) established a task force in 2020 to reassess the inclusion of race in the estimation of GFR in the United States and its implications for diagnosis and subsequent management of patients with, or at risk for, kidney diseases. This interim report details the process, initial assessment of evidence, and values defined regarding the use of race to estimate GFR. We organized activities in phases: (1) clarify the problem and examine evidence, (2) evaluate different approaches to address use of race in GFR estimation, and (3) make recommendations. In phase 1, we constructed statements about the evidence and defined values regarding equity and disparities; race and racism; GFR measurement, estimation, and equation performance; laboratory standardization; and patient perspectives. We also identified several approaches to estimate GFR and a set of attributes to evaluate these approaches. Building on evidence and values, the attributes of alternative approaches to estimate GFR will be evaluated in the next phases and recommendations will be made.